ArticleCancer management and research2020

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients.

Wensi Qian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.